Mast Therapeutics, Inc. (MSTX) - NYSEMKT
  • Mon, Mar. 14, 8:59 AM
    • Mast Therapeutics (MSTX) Q4 results: Revenues: $0; R&D Expense: $7.5M (+53.1%); SG&A: $2.5M (+4.2%); Operating Loss: ($9.7M) (-31.1%); Net Loss: ($10.2M) (-39.7%); Loss Per Share: ($0.06) (-20.0%).
    • FY2015 results: Revenues: $0; R&D Expense: $28.3M (+45.9%); SG&A: $11M (+15.8%); Operating Loss: ($39.4M) (-34.5%); Net Loss: ($39.8M) (-38.7%); Loss Per Share: ($0.25) (-8.7%); Quick Assets: $41M (-28.4%).
    • No guidance given.
    | Mon, Mar. 14, 8:59 AM | 1 Comment
  • Mon, Mar. 14, 8:04 AM
    | Mon, Mar. 14, 8:04 AM | 15 Comments
  • Mon, Feb. 22, 3:30 PM
    • Mast Therapeutics (MSTX +7.7%) completes enrollment of 388 subjects in a Phase 3 clinical trial, EPIC, assessing lead product candidate vepoloxamer for the treatment of patients with sickle cell disease (SCD) experiencing vaso-occlusive crisis (VOC). Top-line results should be available in Q2.
    • EPIC's primary endpoint is the reduction in duration of VOC. Secondary endpoints are rehospitalization rate for VOC and occurrence of acute chest syndrome.
    • Vepoloxamer is a purified form of a copolymer called poloxamer 188, which selectively adheres to hydrophobic (water repelling) portions of cells and molecules, creating a barrier that inhibits other adhesive hydrophobic interactions. The net pharmacologic effects are improved blood flow, blood clot prevention (fibrinolysis) and reductions in inflammation and thrombosis (blood clotting). On a damaged cell, vepoloxamer restores membrane integrity and provides time for the cell's natural repair mechanisms to restore normal function.
    • VOC, a painful complication of SCD, occurs when the circulation of blood vessels is obstructed by sickled red blood cells. One of the most severe forms of VOC is acute chest syndrome which occurs when blood flow to the lungs is restricted.
    | Mon, Feb. 22, 3:30 PM | 1 Comment
  • Wed, Feb. 10, 9:37 AM
    • Mast Therapeutics (MSTX -40.2%) prices its public offering of 29,090,910 units at $0.275 per unit. Each unit consists of one share of common stock and one five-year warrant to purchase one share of common at $0.42. Net proceeds will be ~$7.3M. Closing date is February 16.
    • Net proceeds will fund the clinical development and commercialization of vepoloxamer, working capital and general corporate purposes.
    • Previously: Mast initiates equity offering (Feb. 9)
    | Wed, Feb. 10, 9:37 AM | 3 Comments
  • Tue, Feb. 9, 4:42 PM
    • Mast Therapeutics (NYSEMKT:MSTX) commences a public offering of stock and warrants. Price, volume and terms have yet to be announced. Net proceeds will fund the clinical development and commercialization of vepoloxamer, working capital and general corporate purposes.
    | Tue, Feb. 9, 4:42 PM | 11 Comments
  • Nov. 12, 2015, 4:08 PM
    • Mast Therapeutics (NYSEMKT:MSTX): Q3 EPS of -$0.06 in-line.
    | Nov. 12, 2015, 4:08 PM
  • Oct. 26, 2015, 11:58 AM
    • Mast Therapeutics (MSTX -0.7%) commences a Phase 2 clinical trial assessing lead product candidate vepoloxamer for the treatment of chronic heart failure. The 150-subject, randomized, double-blind, placebo-controlled study will assess a new formulation of vepoloxamer (MST-188) in ambulatory patients, ages 18 to 74, diagnosed with Class II or III chronic heart failure who are stable and well-managed, on an established medication regimen for at least four months, have a left ventricular ejection fraction of no more than 35% and have an elevated cardiac troponin I level in the blood.
    • Patients will be randomized to receive one of two doses of vepoloxamer or placebo as a single intravenous infusion over three hours in a non-hospital setting. The study's objective is to assess if vepoloxamer provides a functional and biochemical benefit to damaged heart muscle cells as measured by echocardiograms and blood-based laboratory tests. It will also evaluate vepoloxamer's safety and pharmacokinetics.
    • Vepoloxamer is a purified form of poloxamer 188, which selectively adheres to hydrophobic (water repelling) portions of cells and molecules, creating a barrier that inhibits other adhesive hydrophobic interactions. The net pharmacologic effects are improved blood flow, blood clot prevention (fibrinolysis) and reductions in inflammation and thrombosis (blood clotting). On a damaged cell, vepoloxamer restores membrane integrity and provides time for the cell's natural repair mechanisms to restore normal function.
    • The estimated study completion date is not provided.
    | Oct. 26, 2015, 11:58 AM | 4 Comments
  • Aug. 12, 2015, 4:06 PM
    • Mast Therapeutics (NYSEMKT:MSTX): Q2 EPS of -$0.06 in-line.
    | Aug. 12, 2015, 4:06 PM | 4 Comments
  • May 11, 2015, 10:16 AM
    • Mast Therapeutics (MSTX) Q1 results: Revenues: $0; R&D Expense: $6M (+39.5%); SG&A: $3.6M (+56.5%); Operating Loss: ($9.7M) (-42.6%); Net Loss: ($9.6M) (-50.0%); Loss Per Share: ($0.06) (unch); Quick Assets: $49.9M (-12.9%).
    • No guidance given.
    | May 11, 2015, 10:16 AM
  • May 11, 2015, 8:26 AM
    • Mast Therapeutics (NYSEMKT:MSTX): Q1 EPS of -$0.06 in-line.
    | May 11, 2015, 8:26 AM | 5 Comments
  • Mar. 24, 2015, 8:13 AM
    • Mast Therapeutics (MSTX +5.7%) Q4 results: Revenues: $0; R&D Expense: $4.9M (+40.0%); SG&A: $2.4M (+14.3%); Operating Loss: ($7.4M) (-29.8%); Net Loss: ($7.3M) (-28.1%); Loss Per Share: ($0.05) (-16.7%).
    • FY2014 results: Revenues: $0; R&D Expense: $19.4M (+50.4%); SG&A: $9.5M (+11.8%); Operating Loss: ($29.3M) (-36.3%); Net Loss: ($28.7M) (-33.5%); Loss Per Share: ($0.23) (+17.9%); Quick Assets: $57.3M (+29.1%).
    • No guidance given.
    | Mar. 24, 2015, 8:13 AM
  • Mar. 24, 2015, 8:03 AM
    • Mast Therapeutics (NYSEMKT:MSTX): Q4 EPS of -$0.05 beats by $0.01.
    | Mar. 24, 2015, 8:03 AM
  • Dec. 3, 2014, 3:36 PM
    • Actelion Ltd (OTCPK:ALIOF) (OTC:ALIOY) submits a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for Uptravi (selexipag) for the treatment of patients with pulmonary arterial hypertension (PAH).
    • Selexipag is selective IP prostacyclin receptor agonist. Prostacyclin activates the IP receptor inducing vasodilation and inhibiting proliferation of vascular smooth muscle cells. If approved, it will be the first such drug cleared for use in PAH.
    • In April 2008, the company signed a license agreement with Nippon Shinyaku under which Actelion has global development and commercialization rights to selexipag outside of Japan. The firms will be partners in Japan.
    • Actelion plans to submit an NDA to the FDA shortly.
    • PAH-related tickers: (GSK -0.8%)(GILD -1.9%)(MSTX -1.5%)(ARNA +1.7%)(OTCPK:BAYRY -1.8%)(UTHR -1.2%)
    | Dec. 3, 2014, 3:36 PM | 4 Comments
  • Sep. 8, 2014, 10:02 AM
    • Shares of Mast Therapeutics (MSTX +7%) jump in response to its report of positive results from a Phase 2 clinical trial evaluating the safety and efficacy of AIR001 (sodium nitrite) for the treatment of patients with pulmonary arterial hypertension (PAH). In the primary efficacy analysis, all doses showed improvement in median vascular resistance (PVR). In the secondary efficacy analysis, all doses showed improvements in the median distances achieved in the 6-minute walk test, including clinically-meaningful improvements at the highest dose level. Whether the results are statistically significant is unknown.
    • Methemoglobin levels remained normal (<1.5%) which is a positive since elevated levels are associated with IV-administered nitrite.
    • Mast obtained the rights to AIR001 from its acquisition of privately-held Aires Pharmaceuticals in February of this year.
    • The study was powered to enroll 90 patients but Aires discontinued enrollment due to the lack of capital. The reported data is from 29 subjects.
    | Sep. 8, 2014, 10:02 AM
  • Aug. 11, 2014, 11:03 AM
    • Mast Therapeutics (MSTX) Q2 results: Revenues: $0; Net Loss: ($7.2M) (-44.7%); Loss Per Share: ($0.06) (+33.3%); Quick Assets: $46.4M (+4.5%).
    • No financial guidance given.
    | Aug. 11, 2014, 11:03 AM
  • Aug. 11, 2014, 8:07 AM
    • Mast Therapeutics (NYSEMKT:MSTX): Q2 EPS of -$0.06 in-line.
    | Aug. 11, 2014, 8:07 AM
Company Description
Mast Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapies for serious or life-threatening diseases with significant unmet needs. It provides products MST-188 has cytoprotective and hemorheologic properties and inhibits inflammatory processes and... More
Sector: Healthcare
Industry: Biotechnology
Country: United States